These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 940666)

  • 1. [Cellular immunity in patients with malignant lymphoma].
    Klára S; Endre K; Tibor C
    Orv Hetil; 1976 Jul; 117(30):1811-4. PubMed ID: 940666
    [No Abstract]   [Full Text] [Related]  

  • 2. Cellular immune responses and prognosis in malignant lymphomas.
    Sokal JE; Aungst CW
    Natl Cancer Inst Monogr; 1971 Dec; 34():109-12. PubMed ID: 4946576
    [No Abstract]   [Full Text] [Related]  

  • 3. [Immunity, leukemias and lymphomas. 3. Immune reactions in malignant granuloma in relationship to the clinical stage of the disease].
    Danieli G; Malini PL; Montroni M; Cremonini G; Lauria F; Tura S
    G Clin Med; 1972 Apr; 53(4):179-95. PubMed ID: 4651225
    [No Abstract]   [Full Text] [Related]  

  • 4. [Immunity, leukemias and lymphomas. 5. Effects of splenectomy on the immunological condition of patients with malignant granuloma].
    Danieli G; Malini PL; Montro NI M; Cremonini G; Lauria F; Tura S
    G Clin Med; 1972 Jun; 53(6):277-89. PubMed ID: 4655306
    [No Abstract]   [Full Text] [Related]  

  • 5. [Immunity, leukemias and lymphomas. IV. Study of immunological reactivity in malignant granuloma in relationship to the histological type].
    Danieli G; Malini PL; Montroni M; Cremonini G; Lauria F
    G Clin Med; 1972 May; 53(5):250-61. PubMed ID: 4655304
    [No Abstract]   [Full Text] [Related]  

  • 6. The immediate effects of splenectomy, radiotherapy and intensive chemotherapy on the immune status of patients with malignant lymphoma.
    Hancock BW; Bruce L; Ward AM; Richmond J
    Clin Oncol; 1977 Jun; 3(2):137-44. PubMed ID: 872467
    [No Abstract]   [Full Text] [Related]  

  • 7. Cytomegalovirus-specific immune response and the cellular immune status of malignant lymphoma.
    ten Napel CH; van Egten-Bijker J; Halie MR; Langenhuysen MM; The TH
    J Clin Lab Immunol; 1980 Nov; 4(3):145-51. PubMed ID: 6259357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immunity, leukemias and lymphomas. VI. Immunological state of splenectomized patients with malignant granuloma, in relation to the histological type of the disease].
    Danieli G; Malini PL; Montroni M; Cremonini G; Lauria F
    G Clin Med; 1972 Jul; 53(7):334-43. PubMed ID: 4666411
    [No Abstract]   [Full Text] [Related]  

  • 9. Blastogenic transformation of lymphocytes following phytohaemagglutinin treatment in vitro in malignant lymphomas. I. Hodgkin's disease. (Correlation with immunity response of the cellular type and with the clinical status).
    Libánský J; Lukásová M; Pinosová I
    Neoplasma; 1973; 20(1):51-60. PubMed ID: 4702205
    [No Abstract]   [Full Text] [Related]  

  • 10. Correlation between mixed lymphocyte cultures and anti-Epstein Barr virus (EBV) antibodies in Hodgkin's disease and non Hodgkin lymphoma patients.
    Sasiain MC; Fejes M; Ares BR; Brezavscek D; Bachmann AE
    Biomedicine; 1981 Oct; 35(5):153-6. PubMed ID: 6274439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delayed-type hypersensitivity and immunoglobulin levels in the course of chemotherapy of advanced malignant neoplasms.
    Singer Z; Salwa J
    Arch Immunol Ther Exp (Warsz); 1973; 21(2):239-47. PubMed ID: 4581915
    [No Abstract]   [Full Text] [Related]  

  • 12. Delayed cutaneous hypersensitivity and blood lymphocyte count in advanced Hodgkin's and non-Hodgkin's lymphomas.
    Gupta S; Seth SK; Udupa KN; Sen PC; Rastogi BL
    Ann Chir Gynaecol; 1980; 69(2):79-83. PubMed ID: 7377739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphocyte sensitivity and cellular immunity in neoplasia.
    Faguet GB; Balcerzak SP; Lobuglio AF
    Biomedicine; 1973 Feb; 19(2):43-7. PubMed ID: 4731978
    [No Abstract]   [Full Text] [Related]  

  • 14. [Serum and immunological studies in patients with lymphomas. 13. Examination of cellular immunity by specific and nonspecific stimulants].
    Giraudo Conesa LC; Braun M; Pavlovsky A; Bachmann AE
    Sangre (Barc); 1973; 18(3):305-12. PubMed ID: 4800716
    [No Abstract]   [Full Text] [Related]  

  • 15. [Lymphomas and immunity].
    Kouvalainen K
    Duodecim; 1970; 86(16):886-94. PubMed ID: 4917099
    [No Abstract]   [Full Text] [Related]  

  • 16. Responses to tests of cell mediated immunity before, during and after BCG administration in Hodgkin's disease.
    Lenzini L; Bracci R; Rottoli P; Rottoli L
    Boll Ist Sieroter Milan; 1974; 53(1):suppl:300. PubMed ID: 4546904
    [No Abstract]   [Full Text] [Related]  

  • 17. [Immunosuppression: a paraneoplastic syndrome].
    Nagel GA
    Schweiz Med Wochenschr; 1971 Apr; 101(13):470-4. PubMed ID: 5283773
    [No Abstract]   [Full Text] [Related]  

  • 18. [Tuberculosis in the course of Hodgkin's disease].
    Leménager J; Tanguy A; Bérnard Y
    Cah Med; 1972 Apr; 13(5):357-62. PubMed ID: 5055112
    [No Abstract]   [Full Text] [Related]  

  • 19. Humoral cross immunity in patients with malignant tumors.
    Harlozinska A; Albert Z; Richter R; Singer Z; Salwa J
    Arch Immunol Ther Exp (Warsz); 1971; 19(6):835-49. PubMed ID: 4946994
    [No Abstract]   [Full Text] [Related]  

  • 20. Invited discussion: relationship of titers of Epstein-Barr virus to cell-mediated immunity in patients with Hodgkin's disease.
    Levine PH; Reisher JI
    Natl Cancer Inst Monogr; 1973 May; 36():85-7. PubMed ID: 4355354
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.